Reviva Competitors

Delisted . USA . 
Stock . Reviva Pharmaceuticals Holdings
RVPHWDelisted Stock  USD 0  0  25.00%   
Reviva Pharmaceuticals competes with MAIA Biotechnology, Skye Bioscience, Century Therapeutics, Actinium Pharmaceuticals, and Bioatla; as well as few others. The company classifies itself under Pharmaceuticals sector and is part of Health Care industry. Analyzing Reviva Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Reviva Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Reviva Pharmaceuticals vs Celularity Correlation

Poor diversification

The correlation between Reviva Pharmaceuticals Holding and CELU is 0.74 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Reviva Pharmaceuticals Holding and CELU in the same portfolio, assuming nothing else is changed.

Moving against Reviva Stock

  0.87MRK Merck CompanyPairCorr
  0.8WMT Walmart Common Stock Sell-off TrendPairCorr
  0.78XOM Exxon Mobil Corp Earnings Call This WeekPairCorr
  0.77PPERF Bank Mandiri PerseroPairCorr
  0.74CAT Caterpillar Earnings Call This WeekPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.00013.27
Details
Intrinsic
Valuation
LowRealHigh
0.00013.27
Details
Naive
Forecast
LowNextHigh
0.00010.0113.28
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.00560.020.05
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Reviva Pharmaceuticals. Your research has to be compared to or analyzed against Reviva Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Reviva Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Reviva Pharmaceuticals.

Reviva Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Reviva Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Reviva and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Reviva Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

CELU
+ 0.9
KLTO
KLTO
+ 0.89
SKYE
IPSC
+ 0.81
MAIA
CELU
+ 0.8
SKYE
ATHE
+ 0.79
KLTO
ATHE
+ 0.77
SKYE
  

High negative correlations

BCAB
- 0.81
IPSC
BCAB
- 0.75
MAIA
KLTO
- 0.7
IPSC
CELU
- 0.65
IPSC
IPSC
- 0.56
SKYE
KLTO
- 0.54
MAIA

Risk-Adjusted Indicators

There is a big difference between Reviva Stock performing well and Reviva Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Reviva Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MAIA  5.41  1.20  0.19  1.92  5.63 
(6.19)
 11.32 
(8.28)
 35.91 
SKYE  4.86 (0.36) 0.00 (0.14) 0.00 
 0.00 
 10.19 
(7.63)
 24.11 
IPSC  5.81  2.47  0.38  1.75  4.52 
(7.90)
 13.95 
(8.26)
 55.97 
ATNM  3.33 (0.08) 0.00 (0.08) 0.00 
 0.00 
 6.29 
(5.33)
 25.17 
BCAB  6.53 (0.27) 0.00  0.18  0.00 
 0.00 
 15.28 
(16.25)
 54.11 
KLTO  4.56 (0.97) 0.00 (0.22) 0.00 
 0.00 
 10.34 
(8.57)
 28.13 
LTRN  3.49 (0.31) 0.00 (0.09) 0.00 
 0.00 
 10.27 
(5.57)
 23.91 
BTAI  4.02 (0.21) 0.00  1.76  0.00 
 0.00 
 8.90 
(7.32)
 21.49 
ATHE  3.17 (0.56) 0.00 (0.18) 0.00 
 0.00 
 5.71 
(8.48)
 17.55 
CELU  3.61 (0.62) 0.00 (0.49) 0.00 
 0.00 
 9.01 
(8.97)
 26.97 

Reviva Pharmaceuticals Competitive Analysis

The better you understand Reviva Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Reviva Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Reviva Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
RVPHW MAIA SKYE IPSC ATNM BCAB KLTO LTRN BTAI ATHE
 25.00 
 0 
Reviva
 6.67 
 2.56 
MAIA
 3.81 
 1.01 
Skye
 4.76 
 2.42 
Century
 1.52 
 1.34 
Actinium
 9.37 
 0.35 
Bioatla
 2.94 
 0.33 
Klotho
 1.98 
 3.46 
Lantern
 0.55 
 1.82 
BioXcel
 8.56 
 3.55 
Alterity
Market Volatility
(90 Days Market Risk)
Out of control
Very risky
Very risky
Dangerous
Very risky
Dangerous
Out of control
Slightly risky
Relatively risky
Moderately volatile
Market Performance
(90 Days Performance)
Weakest
Good
Weakest
Solid
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
High
Small
Moderate
Low
Risky
Small
Low
Risky
Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Current Ratio
0.03
2.78
0.91
17.79
18.83
7.48
N/A
12.38
12.25
7.07
Net Asset
15.5 M
10.16 M
72.76 M
353.22 M
76.9 M
52.42 M
2.46 M
25.57 M
38.34 M
46.03 M
Profit Margin
N/A
N/A
N/A
-0.23
N/A
N/A
N/A
N/A
N/A
-2.23
EBITDA
(29.88 M)
(23.25 M)
(25.29 M)
(111.47 M)
(37.43 M)
(73.02 M)
(5.79 M)
(22.2 M)
(44.16 M)
(14.63 M)
Current Valuation
N/A
83.91 M
(3.55 M)
114.11 M
(11.69 M)
17.07 M
25.94 M
25.93 M
112.91 M
31.81 M
Price To Book
N/A
2275.08
0.97
1.15
2.94
2.68
2.49
3.98
3.97
2.22
Operating Margin
N/A
N/A
N/A
-0.2
-63.24
N/A
N/A
N/A
-143.2
-1.86
Retained Earnings
(164.27 M)
(87.23 M)
(130.95 M)
(782.34 M)
(375.83 M)
(486.04 M)
(10.56 M)
(76.03 M)
(650.2 M)
(225.89 M)
Current Asset
N/A
N/A
N/A
N/A
26.48 M
N/A
N/A
N/A
609.37 K
14.26 M
Beta
-0.028
-0.048
2.68
1.73
-0.3
1.03
2.48
1.58
0.22
0.02
Number Of Employees
14
13
16
140
25
61
3
24
37
9
Shares Outstanding
N/A
37.03 M
32.06 M
87.41 M
31.2 M
64.04 M
72.54 M
11.18 M
21.87 M
18.13 M
Cash Flow From Operations
(33.54 M)
(15.7 M)
(25.24 M)
(110.14 M)
(33.07 M)
(71.94 M)
(2.95 M)
(17.81 M)
(72.03 M)
(11.45 M)
Total Debt
458.15 K
6.52 M
455.59 K
53.83 M
1.57 M
836 K
271.75 K
243.66 K
102.95 M
155.46 K
Return On Equity
-9.16
-26.91
-0.94
-0.14
-1.33
-8.14
-1.98
-1.05
-17.67
-0.43
Return On Asset
-1.3
-1.48
-0.55
-0.0447
-0.34
-1.05
-0.72
-0.56
-0.67
-0.28
Number Of Shares Shorted
7.7 K
1.65 M
998.73 K
325.39 K
875.5 K
4.32 M
482.73 K
283.12 K
1.03 M
238
Book Value Per Share
0.047
0.001
1.06
2.04
0.44
-0.53
0.14
0.87
-4.45
0.0034
Current Liabilities
N/A
N/A
N/A
N/A
4.61 M
N/A
N/A
N/A
1.67 M
1.73 M
Total Asset
15.5 M
10.16 M
72.76 M
353.22 M
76.9 M
52.42 M
2.46 M
25.57 M
38.34 M
46.03 M
Short Ratio
N/A
1.59
2.04
0.23
4.63
2.81
0.61
4.41
2.18
0.01
Target Price
N/A
12.14
8.25
3.5
5.0
10.0
N/A
22.0
16.75
12.0
Debt To Equity
N/A
N/A
0.84
0.12
0.033
0.028
N/A
0.002
0.38
0.003
Shares Owned By Institutions
N/A
6.4
62.77
74.53
19.94
28.6
2.6
20.42
12.1
1.85
Market Capitalization
85.81 M
94.8 M
33.66 M
211.52 M
40.55 M
20.51 M
24.74 M
39.48 M
39.8 M
64.35 M
Price To Earning
N/A
N/A
N/A
86.08
-1.45
N/A
N/A
N/A
-2.62
-4.84
Price To Earnings To Growth
N/A
N/A
N/A
0.26
N/A
N/A
N/A
N/A
-0.01
N/A
Price To Sales
N/A
N/A
N/A
1.87
450.61
4.22
N/A
N/A
52.93
11.83
Net Income
(29.92 M)
(23.25 M)
(26.57 M)
(126.57 M)
(38.24 M)
(69.78 M)
(6.15 M)
(20.78 M)
(59.6 M)
(12.15 M)
Earnings Per Share
N/A
-0.74
-1.3
-0.32
-1.11
-1.15
-0.3
-1.75
-9.29
-0.63
Shares Owned By Insiders
N/A
19.81
1.39
25.47
2.36
11.07
21.23
13.6
4.2
N/A
Revenue
N/A
N/A
N/A
6.59 M
N/A
11 M
N/A
N/A
2.27 M
5.44 M
Working Capital
81.86 K
6.32 M
66.49 M
64.27 M
66.36 M
36.69 M
(1.09 M)
20.92 M
15.16 M
42.34 M
Cash And Equivalents
353.26 K
8.15 M
2.93 M
378.76 M
116.33 M
178.12 M
N/A
62.15 M
233.45 M
34.81 M
Cash Per Share
0.02
0.75
0.01
6.43
4.62
4.77
N/A
5.74
8.33
0.87
Gross Profit
N/A
N/A
N/A
7.99 M
90 K
(46.73 M)
N/A
N/A
(212 K)
5.31 M
Day Typical Price
0.0037
2.53
1.02
2.36
1.34
0.36
0.34
3.49
1.83
3.47
Accumulation Distribution
0.4
291500.0
10912.06
428517.0
0.0507
1.2 M
26382.63
1130.79
14649.05
2339.06
Market Facilitation Index
0.002
N/A
N/A
N/A
0.07
N/A
N/A
0.0
N/A
0.0
Daily Balance Of Power
(0.50)
0.3077
(0.67)
0.22
0.2857
0.5
(0.50)
(0.39)
0.1429
0.8485
Period Momentum Indicator
(0)
0.16
(0.04)
0.11
0.02
0.03
(0.01)
(0.07)
0.01
0.28
Rate Of Daily Change
0.75
1.07
0.96
1.05
1.02
1.09
0.97
0.98
1.01
1.09
Day Median Price
0.004
2.52
1.02
2.33
1.35
0.36
0.34
3.5
1.84
3.44
Price Action Indicator
(0)
0.12
(0.03)
0.14
0.005
0.005
(0.01)
(0.07)
(0.01)
0.25
Coefficient Of Variation
(568.26)
569.87
(2,646)
355.34
(13,410)
(2,145)
(804.22)
(2,879)
(2,528)
(1,025)
Mean Deviation
11.06
5.41
4.86
5.81
3.33
6.53
4.56
3.49
4.02
3.17
Jensen Alpha
(3.01)
1.2
(0.36)
2.47
(0.08)
(0.27)
(0.97)
(0.31)
(0.21)
(0.56)
Total Risk Alpha
(4.66)
0.5752
(0.82)
1.72
(0.46)
(1.29)
(1.29)
(0.60)
(0.72)
(0.79)
Sortino Ratio
N/A
0.187
N/A
0.3805
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
39.3
N/A
43.33
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
17.26
7.13
6.17
9.18
4.5
9.13
5.9
4.63
5.31
4.08
Kurtosis
7.0
1.8
0.5003
8.17
2.99
1.77
0.717
1.03
1.58
0.0708
Potential Upside
19.61
11.32
10.19
13.95
6.29
15.28
10.34
10.27
8.9
5.71
Treynor Ratio
5.61
1.92
(0.14)
1.75
(0.08)
0.1802
(0.22)
(0.09)
1.76
(0.18)
Maximum Drawdown
123.46
35.91
24.11
55.97
25.17
54.11
28.13
23.91
21.49
17.55
Variance
297.81
50.78
38.09
84.21
20.22
83.39
34.77
21.43
28.17
16.64
Market Risk Adjusted Performance
5.62
1.93
(0.13)
1.76
(0.07)
0.1902
(0.21)
(0.08)
1.77
(0.17)
Risk Adjusted Performance
(0.12)
0.1374
(0.02)
0.2152
0.0029
(0.02)
(0.08)
(0.02)
(0.02)
(0.06)
Skewness
1.42
0.6564
0.8088
2.1
1.28
0.2721
0.7294
0.8585
0.4544
(0.17)
Semi Deviation
N/A
5.63
N/A
4.52
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.18)
0.1645
(0.05)
0.2729
(0.02)
(0.06)
(0.14)
(0.05)
(0.05)
(0.12)
Value At Risk
(27.12)
(8.28)
(7.63)
(8.26)
(5.33)
(16.25)
(8.57)
(5.57)
(7.32)
(8.48)
Expected Short fall
N/A
(6.19)
N/A
(7.90)
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
6.27
N/A
6.58
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
31.72
N/A
20.43
N/A
N/A
N/A
N/A
N/A
N/A

Reviva Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Reviva Pharmaceuticals Competition

Reviva Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Reviva Pharmaceuticals in relation to its competition. Reviva Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Reviva Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Reviva Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Reviva Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Reviva Pharmaceuticals position

In addition to having Reviva Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Discretionary ETFs Thematic Idea Now

Consumer Discretionary ETFs
Consumer Discretionary ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in Reviva Stock

If you are still planning to invest in Reviva Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reviva Pharmaceuticals' history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Fundamental Analysis
View fundamental data based on most recent published financial statements
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY